Dr Lal PathLabs Approves ₹168 Cr SN Genelab Deal

Lal : The company has approved the acquisition of a 70% stake in SN Genelab Private Ltd for a cash consideration of up to ₹168 crore. The transaction also includes a performance-linked earn-out capped at ₹31.5 crore, taking the potential total consideration to around ₹199.5 crore. The acquisition supports Dr Lal PathLabs’ M&A-led expansion strategy and is expected to strengthen its diagnostic network and market presence. The earn-out structure also links a portion of the consideration to the acquired business’s future performance. Successful integration and realization of operating synergies will remain key monitorables. Stock Commentary: LALPATHLAB: The acquisition is positive as it expands the company’s diagnostic footprint and supports its inorganic growth strategy. The performance-linked earn-out limits upfront risk to some extent, while integration and future profitability will determine the longer-term benefit.